Sandra Lawrynowicz Leibel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sandra Lawrynowicz Leibel has a total of 216 co-authors. Here are the top co-authors by number of shared publications:
- Elizabeth M. Kwong
Sanford Burnham Prebys Medical Discovery Institute, La Jolla, USA
45 shared publications - Alexandra Kuhlmann-Hogan
NOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies, La Jolla, California
44 shared publications - Anna-Maria Globig
Allen Institute for Immunology , Seattle, WA
44 shared publications - Camila Robles-Oteíza
Yale School of Medicine 1 Department of Immunobiology New Haven, CT
44 shared publications - Christian M. Metallo
Salk Institute for Biological Studies, La Jolla, CA, USA
44 shared publications - Deborah Ayeni
Departments of Pathology and Internal Medicine (Section of Medical Oncology), Yale School of Medicine, New Haven, Connecticut
44 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by Springer Nature in Nature Communications
Genome-scale eCLIP mapping of SARS-CoV-2 RNA interactions with NSP8, NSP12, and N reveals regulatory sites
The global impact of the COVID-19 pandemic highlights the need for a deeper understanding of SARS-CoV-2 replication. Although the essential roles of the RNA-dependent RNA polymerase (NSP12), primase (NSP8), and nucleocapsid (N) proteins are established, their contact points with the full-length viral RNA genome during active infection require further characterization. Here, we used enhanced crosslinking and immunoprecipitation (eCLIP) to map direct interactions of NSP8, NSP12, and N across the SARS-CoV-2 genome during live virus infection at early and late stages of replication. We mapped NSP8 and NSP12 binding to the 5′ and 3′ ends of positive- and negative-sense RNA, consistent with their roles in viral replication, transcription, and translation. We also observed an NSP12 binding site within the conserved Y1 domain of NSP3 that modulates RNA and protein abundance. In addition, N binds the 5′ untranslated region (UTR), supporting a role in translational regulation early in infection, and associates with the frameshift element, where it modulates ribosomal frameshifting. Together, these findings map SARS-CoV-2 RNA–protein interactions across the viral genome and delineate specific regulatory regions for potential antiviral intervention.
- 30 October 2026
- Published by Springer Nature in Nature Communications
Open AccessGenome-scale eCLIP mapping of SARS-CoV-2 RNA interactions with NSP8, NSP12, and N reveals regulatory sites
The global impact of the COVID-19 pandemic highlights the need for a deeper understanding of SARS-CoV-2 replication. Although the essential roles of the RNA-dependent RNA polymerase (NSP12), primase (NSP8), and nucleocapsid (N) proteins are established, their contact points with the full-length viral RNA genome during active infection require further characterization. Here, we used enhanced crosslinking and immunoprecipitation (eCLIP) to map direct interactions of NSP8, NSP12, and N across the SARS-CoV-2 genome during live virus infection at early and late stages of replication. We mapped NSP8 and NSP12 binding to the 5′ and 3′ ends of positive- and negative-sense RNA, consistent with their roles in viral replication, transcription, and translation. We also observed an NSP12 binding site within the conserved Y1 domain of NSP3 that modulates RNA and protein abundance. In addition, N binds the 5′ untranslated region (UTR), supporting a role in translational regulation early in infection, and associates with the frameshift element, where it modulates ribosomal frameshifting. Together, these findings map SARS-CoV-2 RNA–protein interactions across the viral genome and delineate specific regulatory regions for potential antiviral intervention.
- Open Access
- 1 July 2026
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 35 (181) , 260061
Occlusive versus non-occlusive CPAP interfaces in neonatal respiratory care: a comparative review of efficacy and safety
Background: Continuous positive airway pressure (CPAP) is first-line therapy for respiratory distress in preterm infants, but optimal interface selection remains controversial. Occlusive interfaces (nasal prongs and masks with tight seals) provide accurate pressure delivery but can cause significant nasal trauma, while non-occlusive interfaces (loosely fitting nasal cannulae) reduce trauma but may compromise therapeutic efficacy. Objective: To synthesise current evidence comparing occlusive with non-occlusive CPAP interfaces regarding pressure delivery accuracy, clinical efficacy, safety outcomes and practical implementation in neonatal intensive care. Methods: Comprehensive review of randomised controlled trials, systematic reviews, bench studies and observational studies comparing CPAP interface types in preterm neonates. Evidence quality assessed using the Grading of Recommendations Assessment, Development and Evaluation criteria where applicable. Results: Occlusive interfaces deliver pressure within 0.5–1.0 cmH 2 O of set values and demonstrate superior efficacy in landmark trials (COIN, SUPPORT), particularly in extremely preterm infants (50% in extremely preterm infants. Conclusions: Current evidence supports occlusive CPAP as first-line therapy for moderate-to-severe respiratory distress in preterm neonates, particularly those of <32 weeks’ gestation. Non-occlusive interfaces may be appropriate for stable infants, weaning support or apnoea of prematurity management. Adequately powered randomised trials stratified by gestational age and respiratory severity are urgently needed to define optimal interface selection strategies.
- 1 July 2026
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 35 (181) , 260061
Open AccessOcclusive versus non-occlusive CPAP interfaces in neonatal respiratory care: a comparative review of efficacy and safety
Background: Continuous positive airway pressure (CPAP) is first-line therapy for respiratory distress in preterm infants, but optimal interface selection remains controversial. Occlusive interfaces (nasal prongs and masks with tight seals) provide accurate pressure delivery but can cause significant nasal trauma, while non-occlusive interfaces (loosely fitting nasal cannulae) reduce trauma but may compromise therapeutic efficacy. Objective: To synthesise current evidence comparing occlusive with non-occlusive CPAP interfaces regarding pressure delivery accuracy, clinical efficacy, safety outcomes and practical implementation in neonatal intensive care. Methods: Comprehensive review of randomised controlled trials, systematic reviews, bench studies and observational studies comparing CPAP interface types in preterm neonates. Evidence quality assessed using the Grading of Recommendations Assessment, Development and Evaluation criteria where applicable. Results: Occlusive interfaces deliver pressure within 0.5–1.0 cmH 2 O of set values and demonstrate superior efficacy in landmark trials (COIN, SUPPORT), particularly in extremely preterm infants (50% in extremely preterm infants. Conclusions: Current evidence supports occlusive CPAP as first-line therapy for moderate-to-severe respiratory distress in preterm neonates, particularly those of <32 weeks’ gestation. Non-occlusive interfaces may be appropriate for stable infants, weaning support or apnoea of prematurity management. Adequately powered randomised trials stratified by gestational age and respiratory severity are urgently needed to define optimal interface selection strategies.
- 31 July 2025
- Published by Springer Nature
- p. 1-18
Derivation of Lung Organoids from Human-Induced Pluripotent Stem Cells for Respiratory Infection Studies
The development of human-induced pluripotent stem cell (hiPSC)-derived lung organoids has revolutionized the study of lung development, disease modeling, and infection systems. These three-dimensional structures recapitulate key features of human lung physiology, including epithelial and mesenchymal interactions, and provide a biologically relevant platform for studying viral infections, epithelial-specific immune responses, and therapeutic interventions. Here, we outline the stepwise derivation of lung organoids from hiPSCs, describe their characterization, and discuss their application in infection modeling.
- 31 July 2025
- Published by Springer Nature
- p. 1-18
Derivation of Lung Organoids from Human-Induced Pluripotent Stem Cells for Respiratory Infection Studies
The development of human-induced pluripotent stem cell (hiPSC)-derived lung organoids has revolutionized the study of lung development, disease modeling, and infection systems. These three-dimensional structures recapitulate key features of human lung physiology, including epithelial and mesenchymal interactions, and provide a biologically relevant platform for studying viral infections, epithelial-specific immune responses, and therapeutic interventions. Here, we outline the stepwise derivation of lung organoids from hiPSCs, describe their characterization, and discuss their application in infection modeling.
- Open Access
Modeling the Aging Human Lung: Generation of a Senescent Human Lung Organoid Culture System
Introduction: The aging lung enters into a state of irreversible cellular growth arrest characterized by senescence. While senescence is beneficial in preventing oncogenic cell proliferation, it becomes detrimental when persistent, promoting chronic inflammation and fibrosis through the senescence-associated secretory phenotype (SASP). Such senescence-related pathophysiological processes play key roles in lung diseases like chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). However, few models accurately represent senescence in the human lung. Methods: To generate a human lung senescence in vitro model, we first generated a human induced pluripotent stem cell (hiPSC)-derived lung organoid (LO) system which was dissociated into monolayers and air-liquid interface (ALI) cultures to enhance visualization and allow uniform exposure to agents. Cellular senescence was induced using doxorubicin, a DNA-damaging agent. Senescence markers, such as β-galactosidase (β-gal) activity, SASP cytokine production and secretion, cell morphology, proliferative capacity, and barrier integrity were evaluated to validate the senescent phenotype. Results: The doxorubicin-induced senescent hiPSC-derived lung cells demonstrated the hallmark characteristics of cellular senescence, including increased β-gal activity and increased production of the pro-inflammatory SASP cytokine IL-6 and increased secretion of TNF-α. Senescent cells displayed enlarged morphology, decreased proliferation, and reduced wound repair capacity. Barrier integrity was impaired with decreased electrical resistance, and increased permeability, as well as expression of abnormal tight junction proteins and increased fibrosis, all consistent with the senescent lung. Conclusion: Our hiPSC-derived lung cell senescent model reproduces key aspects of human lung senescence and offer an in vitro tool for studying age-related lung disease mechanisms and therapeutic interventions. This model has potential applications in exploring the impact of environmental factors (e.g., toxins, infectious pathogens, etc.) on the senescent lung and assessing treatments that could mitigate pathologies associated with pulmonary aging including barrier impairment, inflammation and fibrosis.
Open AccessModeling the Aging Human Lung: Generation of a Senescent Human Lung Organoid Culture System
Introduction: The aging lung enters into a state of irreversible cellular growth arrest characterized by senescence. While senescence is beneficial in preventing oncogenic cell proliferation, it becomes detrimental when persistent, promoting chronic inflammation and fibrosis through the senescence-associated secretory phenotype (SASP). Such senescence-related pathophysiological processes play key roles in lung diseases like chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). However, few models accurately represent senescence in the human lung. Methods: To generate a human lung senescence in vitro model, we first generated a human induced pluripotent stem cell (hiPSC)-derived lung organoid (LO) system which was dissociated into monolayers and air-liquid interface (ALI) cultures to enhance visualization and allow uniform exposure to agents. Cellular senescence was induced using doxorubicin, a DNA-damaging agent. Senescence markers, such as β-galactosidase (β-gal) activity, SASP cytokine production and secretion, cell morphology, proliferative capacity, and barrier integrity were evaluated to validate the senescent phenotype. Results: The doxorubicin-induced senescent hiPSC-derived lung cells demonstrated the hallmark characteristics of cellular senescence, including increased β-gal activity and increased production of the pro-inflammatory SASP cytokine IL-6 and increased secretion of TNF-α. Senescent cells displayed enlarged morphology, decreased proliferation, and reduced wound repair capacity. Barrier integrity was impaired with decreased electrical resistance, and increased permeability, as well as expression of abnormal tight junction proteins and increased fibrosis, all consistent with the senescent lung. Conclusion: Our hiPSC-derived lung cell senescent model reproduces key aspects of human lung senescence and offer an in vitro tool for studying age-related lung disease mechanisms and therapeutic interventions. This model has potential applications in exploring the impact of environmental factors (e.g., toxins, infectious pathogens, etc.) on the senescent lung and assessing treatments that could mitigate pathologies associated with pulmonary aging including barrier impairment, inflammation and fibrosis.
- 7 December 2024
- Published by MyJove Corporation
- No. 214,p. e67247
JoVE Video Dataset
Human lung tissue is composed of an interconnected network of epithelium, mesenchyme, endothelium, and immune cells from the upper airway of the nasopharynx to the smallest alveolar sac. Interactions between these cells are crucial in lung development and disease, acting as a barrier against harmful chemicals and pathogens. Current in vitro co-culture models utilize immortalized cell lines with different biological backgrounds, which may not accurately represent the cellular milieu or interactions of the lung. We differentiated human iPSCs into 3D lung organoids (containing both epithelium and mesenchyme), endothelial cells, and macrophages. These were co-cultured in an air-liquid interface (ALI) format to form an epithelial/mesenchymal apical barrier invested with macrophages and a basolateral endothelial barrier (iAirway). iPSC-derived iAirways showed a reduction in barrier integrity in response to infection with respiratory viruses and cigarette toxins. This multi-lineage lung co-culture system provides a platform for studying cellular interactions, signaling pathways, and molecular mechanisms underlying lung development, homeostasis, and disease progression. iAirways closely mimic human physiology and cellular interactions, can be generated from patient-derived iPSC's, and can be customized to include different cell types of the airway. Overall, iPSC-derived iAirway models offer a versatile and powerful tool for studying barrier integrity to better understand genetic drivers for disease, pathogen response, immune regulation, and drug discovery or repurposing in vitro, with the potential to advance our understanding and treatment of airway diseases.
- 7 December 2024
- Published by MyJove Corporation
- No. 214,p. e67247
JoVE Video Dataset
Human lung tissue is composed of an interconnected network of epithelium, mesenchyme, endothelium, and immune cells from the upper airway of the nasopharynx to the smallest alveolar sac. Interactions between these cells are crucial in lung development and disease, acting as a barrier against harmful chemicals and pathogens. Current in vitro co-culture models utilize immortalized cell lines with different biological backgrounds, which may not accurately represent the cellular milieu or interactions of the lung. We differentiated human iPSCs into 3D lung organoids (containing both epithelium and mesenchyme), endothelial cells, and macrophages. These were co-cultured in an air-liquid interface (ALI) format to form an epithelial/mesenchymal apical barrier invested with macrophages and a basolateral endothelial barrier (iAirway). iPSC-derived iAirways showed a reduction in barrier integrity in response to infection with respiratory viruses and cigarette toxins. This multi-lineage lung co-culture system provides a platform for studying cellular interactions, signaling pathways, and molecular mechanisms underlying lung development, homeostasis, and disease progression. iAirways closely mimic human physiology and cellular interactions, can be generated from patient-derived iPSC's, and can be customized to include different cell types of the airway. Overall, iPSC-derived iAirway models offer a versatile and powerful tool for studying barrier integrity to better understand genetic drivers for disease, pathogen response, immune regulation, and drug discovery or repurposing in vitro, with the potential to advance our understanding and treatment of airway diseases.
- 6 December 2024
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 214,p. e67247
iPSC-Derived Epithelial, Mesenchymal, Endothelial, and Immune Cell Co-Culture to Model Airway Barrier Integrity in Lung Health and Disease
Human lung tissue is composed of an interconnected network of epithelium, mesenchyme, endothelium, and immune cells from the upper airway of the nasopharynx to the smallest alveolar sac. Interactions between these cells are crucial in lung development and disease, acting as a barrier against harmful chemicals and pathogens. Current in vitro co-culture models utilize immortalized cell lines with different biological backgrounds, which may not accurately represent the cellular milieu or interactions of the lung. We differentiated human iPSCs into 3D lung organoids (containing both epithelium and mesenchyme), endothelial cells, and macrophages. These were co-cultured in an air-liquid interface (ALI) format to form an epithelial/mesenchymal apical barrier invested with macrophages and a basolateral endothelial barrier (iAirway). iPSC-derived iAirways showed a reduction in barrier integrity in response to infection with respiratory viruses and cigarette toxins. This multi-lineage lung co-culture system provides a platform for studying cellular interactions, signaling pathways, and molecular mechanisms underlying lung development, homeostasis, and disease progression. iAirways closely mimic human physiology and cellular interactions, can be generated from patient-derived iPSC's, and can be customized to include different cell types of the airway. Overall, iPSC-derived iAirway models offer a versatile and powerful tool for studying barrier integrity to better understand genetic drivers for disease, pathogen response, immune regulation, and drug discovery or repurposing in vitro, with the potential to advance our understanding and treatment of airway diseases.
- 6 December 2024
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 214,p. e67247
iPSC-Derived Epithelial, Mesenchymal, Endothelial, and Immune Cell Co-Culture to Model Airway Barrier Integrity in Lung Health and Disease
Human lung tissue is composed of an interconnected network of epithelium, mesenchyme, endothelium, and immune cells from the upper airway of the nasopharynx to the smallest alveolar sac. Interactions between these cells are crucial in lung development and disease, acting as a barrier against harmful chemicals and pathogens. Current in vitro co-culture models utilize immortalized cell lines with different biological backgrounds, which may not accurately represent the cellular milieu or interactions of the lung. We differentiated human iPSCs into 3D lung organoids (containing both epithelium and mesenchyme), endothelial cells, and macrophages. These were co-cultured in an air-liquid interface (ALI) format to form an epithelial/mesenchymal apical barrier invested with macrophages and a basolateral endothelial barrier (iAirway). iPSC-derived iAirways showed a reduction in barrier integrity in response to infection with respiratory viruses and cigarette toxins. This multi-lineage lung co-culture system provides a platform for studying cellular interactions, signaling pathways, and molecular mechanisms underlying lung development, homeostasis, and disease progression. iAirways closely mimic human physiology and cellular interactions, can be generated from patient-derived iPSC's, and can be customized to include different cell types of the airway. Overall, iPSC-derived iAirway models offer a versatile and powerful tool for studying barrier integrity to better understand genetic drivers for disease, pathogen response, immune regulation, and drug discovery or repurposing in vitro, with the potential to advance our understanding and treatment of airway diseases.
- Open Access
- 13 August 2024
- Published by Springer Nature in Pediatric Research
- Vol. 97 (3) , 1227-1236
The impact of breastfeeding on the preterm infant’s microbiome and metabolome: a pilot study
Background: Human milk is unquestionably beneficial for preterm infants. We investigated how the transition from tube to oral/breastfeeding impacts the preterm infants’ oral and gut microbiome and metabolome. Methods: We analyzed stool, saliva, and milk samples collected from a cohort of preterm infants enrolled in the MAP Study, a prospective observational trial. The microbiome and metabolome of the samples were analyzed from 4 longitudinal sample time points, 2 during tube feeds only and 2 after the initiation of oral/breastfeeding. Results: We enrolled 11 mother-infant dyads (gestational age = 27.9 (23.4–32.2)) and analyzed a total of 39 stool, 44 saliva, and 43 milk samples over 4 timepoints. In saliva samples, there was a shift towards increased Streptococcus and decreased Staphylococcus after oral feeding/breastfeeding initiation (p < 0.05). Milk sample metabolites were strongly influenced by the route of feeding and milk type (p < 0.05) and represented the pathways of Vitamin E metabolism, Vitamin B12 metabolism, and Tryptophan metabolism. Conclusion: Our analysis demonstrated that the milk and preterm infant’s saliva microbiome and metabolome changed over the course of the first four to 5 months of life, coinciding with the initiation of oral/breastfeeds. Impact: The microbiome and metabolome is altered in the infant’s saliva but not their stool, and in mother’s milk when feeds are transitioned from tube to oral/breastfeeding. We assessed the relationship between the gut and oral microbiome/metabolome with the milk microbiome/metabolome over a longitudinal period of time in preterm babies. Metabolites that changed in the infants saliva after the initiation of oral feeds have the potential to be used as biomarkers for disease risk.
- 13 August 2024
- Published by Springer Nature in Pediatric Research
- Vol. 97 (3) , 1227-1236
Open AccessThe impact of breastfeeding on the preterm infant’s microbiome and metabolome: a pilot study
Background: Human milk is unquestionably beneficial for preterm infants. We investigated how the transition from tube to oral/breastfeeding impacts the preterm infants’ oral and gut microbiome and metabolome. Methods: We analyzed stool, saliva, and milk samples collected from a cohort of preterm infants enrolled in the MAP Study, a prospective observational trial. The microbiome and metabolome of the samples were analyzed from 4 longitudinal sample time points, 2 during tube feeds only and 2 after the initiation of oral/breastfeeding. Results: We enrolled 11 mother-infant dyads (gestational age = 27.9 (23.4–32.2)) and analyzed a total of 39 stool, 44 saliva, and 43 milk samples over 4 timepoints. In saliva samples, there was a shift towards increased Streptococcus and decreased Staphylococcus after oral feeding/breastfeeding initiation (p < 0.05). Milk sample metabolites were strongly influenced by the route of feeding and milk type (p < 0.05) and represented the pathways of Vitamin E metabolism, Vitamin B12 metabolism, and Tryptophan metabolism. Conclusion: Our analysis demonstrated that the milk and preterm infant’s saliva microbiome and metabolome changed over the course of the first four to 5 months of life, coinciding with the initiation of oral/breastfeeds. Impact: The microbiome and metabolome is altered in the infant’s saliva but not their stool, and in mother’s milk when feeds are transitioned from tube to oral/breastfeeding. We assessed the relationship between the gut and oral microbiome/metabolome with the milk microbiome/metabolome over a longitudinal period of time in preterm babies. Metabolites that changed in the infants saliva after the initiation of oral feeds have the potential to be used as biomarkers for disease risk.
- Open Access
- 19 July 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (30)
A therapy for suppressing canonical and noncanonical SARS-CoV-2 viral entry and an intrinsic intrapulmonary inflammatory response
The prevalence of “long COVID” is just one of the conundrums highlighting how little we know about the lung’s response to viral infection, particularly to syndromecoronavirus-2 (SARS-CoV-2), for which the lung is the point of entry. We used an in vitro human lung system to enable a prospective, unbiased, sequential single-cell level analysis of pulmonary cell responses to infection by multiple SARS-CoV-2 strains. Starting with human induced pluripotent stem cells and emulating lung organogenesis, we generated and infected three-dimensional, multi-cell-type-containing lung organoids (LOs) and gained several unexpected insights. First, SARS-CoV-2 tropism is much broader than previously believed: Many lung cell types are infectable, if not through a canonical receptor-mediated route (e.g., via Angiotensin-converting encyme 2(ACE2)) then via a noncanonical “backdoor” route (via macropinocytosis, a form of endocytosis). Food and Drug Administration (FDA)-approved endocytosis blockers can abrogate such entry, suggesting adjunctive therapies. Regardless of the route of entry, the virus triggers a lung-autonomous, pulmonary epithelial cell–intrinsic, innate immune response involving interferons and cytokine/chemokine production in the absence of hematopoietic derivatives. The virus can spread rapidly throughout human LOs resulting in mitochondrial apoptosis mediated by the prosurvival protein Bcl-xL. This host cytopathic response to the virus may help explain persistent inflammatory signatures in a dysfunctional pulmonary environment of long COVID. The host response to the virus is, in significant part, dependent on pulmonary Surfactant Protein-B, which plays an unanticipated role in signal transduction, viral resistance, dampening of systemic inflammatory cytokine production, and minimizing apoptosis. Exogenous surfactant, in fact, can be broadly therapeutic.
- 19 July 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (30)
Open AccessA therapy for suppressing canonical and noncanonical SARS-CoV-2 viral entry and an intrinsic intrapulmonary inflammatory response
The prevalence of “long COVID” is just one of the conundrums highlighting how little we know about the lung’s response to viral infection, particularly to syndromecoronavirus-2 (SARS-CoV-2), for which the lung is the point of entry. We used an in vitro human lung system to enable a prospective, unbiased, sequential single-cell level analysis of pulmonary cell responses to infection by multiple SARS-CoV-2 strains. Starting with human induced pluripotent stem cells and emulating lung organogenesis, we generated and infected three-dimensional, multi-cell-type-containing lung organoids (LOs) and gained several unexpected insights. First, SARS-CoV-2 tropism is much broader than previously believed: Many lung cell types are infectable, if not through a canonical receptor-mediated route (e.g., via Angiotensin-converting encyme 2(ACE2)) then via a noncanonical “backdoor” route (via macropinocytosis, a form of endocytosis). Food and Drug Administration (FDA)-approved endocytosis blockers can abrogate such entry, suggesting adjunctive therapies. Regardless of the route of entry, the virus triggers a lung-autonomous, pulmonary epithelial cell–intrinsic, innate immune response involving interferons and cytokine/chemokine production in the absence of hematopoietic derivatives. The virus can spread rapidly throughout human LOs resulting in mitochondrial apoptosis mediated by the prosurvival protein Bcl-xL. This host cytopathic response to the virus may help explain persistent inflammatory signatures in a dysfunctional pulmonary environment of long COVID. The host response to the virus is, in significant part, dependent on pulmonary Surfactant Protein-B, which plays an unanticipated role in signal transduction, viral resistance, dampening of systemic inflammatory cytokine production, and minimizing apoptosis. Exogenous surfactant, in fact, can be broadly therapeutic.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S1 from EGFR-Driven Lung Adenocarcinomas Co-opt Alveolar Macrophage Metabolism and Function to Support EGFR Signaling and Growth
Figure S1: Myeloid cell regulation during lung tumorigenesis.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from EGFR-Driven Lung Adenocarcinomas Co-opt Alveolar Macrophage Metabolism and Function to Support EGFR Signaling and Growth
Figure S1: Myeloid cell regulation during lung tumorigenesis.